Korro Bio rises after HCW starts with 'buy' rating

Korro Bio

04/12/2023 15:42

** Shares of Korro Bio  KRRO.O  rise 4.7% to $51.3 in
morning trade
    ** Brokerage HC Wainwright starts coverage on KRRO with
"buy" rating and PT of $100
    ** HCW says co's gene editing technology is promising as it
modifies course of rare genetic disorder affecting liver and
lungs
     ** In preclinical studies involving mice, co's lead
candidate used drug delivery similar to Alnylam's Onpattro,
supporting quality of trial, however its newer drug delivery
showed higher gene-editing efficiency in lower dosage - HCW    
    ** KRRO is developing its technology for liver inflammation
due to alcoholism, Parkinson's disease and ALS 
    ** Despite session gains, stock down 73% this year

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))